Sigachi laboratories is listed on the Metropolitan Stock Exchange of India. It is having a Regd. Office at S.No. 530 & 534, Bonthapally - 502 313, Gummadidala Mandal, (formerly Jinnaram Mandal), Sangareddy District, (formerly Medak District), Telangana. The company mainly gets its income from Pharmaceutical Products (Bulk Drugs and Drug Intermediates) and Interest on loans/ ICDs, Fixed Deposits.
P&L Statement | 2021 | 2022 | 2023 | 2024 |
---|---|---|---|---|
Revenue | 348 | 260 | 195 | 374 |
Cost of Material Consumed | 0 | 0 | 0 | 0 |
Gross Margins | 100 | 100 | 100 | 100 |
Change in Inventory | 0 | 0 | 0 | 0 |
Employee Benefit Expenses | 29 | 34 | 36 | 39 |
Other Expenses | 26 | 15 | 17 | 93 |
EBITDA | 293 | 211 | 142 | 242 |
OPM | 84.2 | 81.15 | 72.82 | 64.71 |
Other Income | 38 | 44 | 50 | 62 |
Finance Cost | 0 | 0 | 0 | 0 |
D&A | 17 | 17 | 19 | 23 |
EBIT | 276 | 194 | 123 | 219 |
EBIT Margins | 79.31 | 74.62 | 63.08 | 58.56 |
PBT | 314 | 238 | 173 | 281 |
PBT Margins | 90.23 | 91.54 | 88.72 | 75.13 |
Tax (2021) | 38 | 38 | 42 | 84 |
PAT | 276 | 200 | 131 | 197 |
NPM | 79.31 | 76.92 | 67.18 | 52.67 |
EPS | 3.78 | 2.74 | 1.79 | 2.69 |
Financial Ratios | 2021 | 2022 | 2023 | 2024 |
---|---|---|---|---|
Operating Profit Margin | 84.2 | 81.15 | 72.82 | 64.71 |
Net Profit Margin | 79.31 | 76.92 | 67.18 | 52.67 |
Earning Per Share (Diluted) | 3.78 | 2.74 | 1.79 | 2.69 |
Assets | 2021 | 2022 | 2023 | 2024 |
---|---|---|---|---|
Fixed Assets | 246 | 229 | 237 | 321 |
CWIP | 0 | 0 | 0 | 0 |
Investments | 1925 | 2151 | 1966 | 2663 |
Trade Receivables | 0 | 16 | 1 | 20 |
Inventory | 0 | 0 | 0 | 0 |
Other Assets | 567 | 632 | 922 | 730 |
Total Assets | 2738 | 3028 | 3126 | 3734 |
Liabilities | 2021 | 2022 | 2023 | 2024 |
---|---|---|---|---|
Share Capital | 731 | 731 | 731 | 731 |
FV | 10 | 10 | 10 | 10 |
Reserves | 1946 | 2244 | 2343 | 2870 |
Borrowings | 0 | 0 | 0 | 0 |
Trade Payables | 0 | 0 | 0 | 0 |
Other Liabilities | 61 | 53 | 52 | 133 |
Total Liabilities | 2738 | 3028 | 3126 | 3734 |
Cash-Flow Statement | 2021 | 2022 | 2023 | 2024 |
---|---|---|---|---|
PBT | 314 | 237 | 173 | 281 |
OPBWC | 63 | 74 | 77 | 80 |
Change in Receivables | 21 | -16 | 15 | -19 |
Change in Inventories | 0 | 0 | 0 | 0 |
Change in Payables | 0 | 0 | 0 | 0 |
Other Changes | -31 | -236 | 0 | -210 |
Working Capital Change | -10 | -252 | 15 | -229 |
Cash Generated From Operations | 53 | -178 | 92 | -149 |
Tax | -38 | -38 | -44 | -41 |
Cash Flow From Operations | 15 | -216 | 48 | -190 |
Purchase of PPE | -1 | -1.6 | -27 | -108 |
Sale of PPE | 0 | 0.5 | 0 | 2 |
Cash Flow From Investment | 18 | 54 | 243 | -136 |
Borrowing | 0 | 0 | 0 | 0 |
Divided | 0 | 0 | 0 | 0 |
Equity | 0 | 0 | 0 | 0 |
Others From Financing | 0 | 0 | 0 | 0 |
Cash Flow from Financing | 0 | 0 | 0 | 0 |
Net Cash Generated | 33 | -162 | 291 | -326 |
Cash at the Start | 210 | 243 | 80 | 371 |
Cash at the End | 243 | 81 | 371 | 45 |
Shareholding Pattern | 2021 | 2022 | 2023 | 2024 |
---|---|---|---|---|
Promoters | 36.86% | 36.86% | 36.86% | 36.86% |
Resident Individuals | 40.50% | 40.50% | 40.50% | 40.50% |
NRI | 20.67% | 20.67% | 20.67% | 20.67% |
Others | 1.97% | 1.97% | 1.97% | 1.97% |